Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 414 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omega 3 fatty acid Clear all
Completed Not applicable Interventional Results available

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

NCT02445651
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery

NCT00446966
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Omega Three Polyunsaturated fatty acids
Drug
Lead sponsor
Chirag Sandesara
Other
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 1, 2026, 9:53 PM EDT
Not listed Not applicable Interventional

Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG

NCT04117022
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
DVS supplementation
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Pomona, California • Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Early Phase 1 Interventional

Window of Opportunity Study Targeting the Inflammatory Milieu

NCT01881048
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Omega-3 fatty acid, Celecoxib
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

NCT00440050
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
DHA (Docosahexaenoic Acid), Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Fish Oil in Lupus Patients

NCT00828178
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Omega-3, flow-mediated dilation of the brachial artery, corn starch
Drug · Device · Other
Lead sponsor
Michelle Petri M.D.,MPH
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3 Supplementation and Mental Health in College Students

NCT07391254
View directory record Official record
Conditions
Mental Health, Vitamin D
Interventions
Placebo, Low dose Omega 3, High dose Omega 3
Dietary Supplement
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 27 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Omega-3 Supplementation for Pediatric Migraine

NCT06899074
View directory record Official record
Conditions
Migraine
Interventions
Omega 3 Polyunsaturated Fats, Matching Placebo
Dietary Supplement · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

NCT02642159
View directory record Official record
Conditions
Dyslipidemia
Interventions
Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

NCT04177680
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Omega 3 pentaenoic acid, icosapent ethyl
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Jacksonville, Florida • Jupiter, Florida • Port Saint Lucie, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Vitamin D Supplementation on Cardiac Structure and Function

NCT01630213
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Vitamin D3 + fish oil/fish oil placebo, Vitamin D3 placebo + fish oil/fish oil placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
1,025 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 1, 2026, 9:53 PM EDT
Withdrawn Phase 4 Interventional

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

NCT06280976
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Heart Attack
Interventions
Statin, Aspirin tablet, Nexlizet, LEQVIO, Vascepa, Jardiance, Colchicine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3-fatty Acids on Age-related Macular

NCT01258335
View directory record Official record
Conditions
Aged Macular Degeneration
Interventions
Omega 3, Olive Oil
Dietary Supplement · Other
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
20 Years to 49 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Evaluation of Cow Milk-Based Formulas

NCT00518414
View directory record Official record
Conditions
Term Infants
Interventions
Marketed infant formula with DHA and ARA, Milk-based infant formula with DHA and ARA, Milk-based formula with DHA, ARA, prebiotics
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
10 Days to 18 Days
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

NCT01894581
View directory record Official record
Conditions
Obesity, Fertility
Interventions
LOVAZA, GnRH
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Results available

Effect of EPA and HMB on Strength in ICU Patients

NCT01270516
View directory record Official record
Conditions
Muscle Weakness
Interventions
HMB, hydroxymethylbutyrate, EPA, eicosapentaenoic acid, Saline
Drug
Lead sponsor
Gerald Supinski
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional

Testing Fish Oil Derivatives In Healing Of Chronic Venous Leg Ulcers

NCT01754506
View directory record Official record
Conditions
Venous Stasis Ulcers
Interventions
Fish Oil
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 3 Interventional

Omega-3 Fatty Acids for Treating Adults With Major Depression

NCT00517036
View directory record Official record
Conditions
Depression
Interventions
EPA omega-3 fatty acid, DHA omega-3 fatty acid, Placebo comparator
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

NCT00361374
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
eicosapentaenoic acid, docosahexaenoic acid, Placebo
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age

NCT00351624
View directory record Official record
Conditions
Healthy
Interventions
DHA, placebo
Behavioral
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
4 Years to 4 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Stockbridge, Georgia • DeKalb, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 1, 2026, 9:53 PM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT03510884
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 1, 2026, 9:53 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin D and Omega-3 Adiposity Trial (VITAL Adiposity)

NCT01785004
View directory record Official record
Conditions
Adiposity
Interventions
Vitamin D3 (cholecalciferol), 2000 IU per day, omega-3 fatty acids (fish oil)
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 1, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA + DHA in a SMEDS Formulation

NCT03443076
View directory record Official record
Conditions
Bioavailability
Interventions
EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved)
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 1, 2026, 9:53 PM EDT